About the GLASS-ART Trial(TM) (http://www.glassarttrial.com)
The Phase III GLASS-ART Trial derives its name from its description: GBM Locoregional Agent Survival Study - Antitenascin Radiolabeled antibody Therapy Trial. The study is designed to determine the survival benefit derived from, and safety of, adding Neuradiab to the current standard of care therapy for patients diagnosed with primary glioblastoma multiforme. The randomized trial will enroll up to 760 patients at leading treatment centers across the United States. Additional information on the trial can be found at http://www.glassarttrial.com or at http://www.clinicaltrials.gov and then by searching the term "Bradmer" or the study identifier NCT00615186.
Neuradiab is a monoclonal antibody, conjugated to radioactive iodine,
used to treat glioblastoma multiforme (GBM), the most common and most
advanced form of brain cancer. Neuradiab delivers tumor-killing radiation
specifically to residual brain tumor cells after surgery, with minimal
impact on normal brain tissue. During the course of development at Duke
University, over US$60 million in research grants and related support has
produced a series of Phase I and Phase II clinical trials on Neuradiab and
other closely related technologies. Approximately 200 brain cancer
patients, including over 160 with GBM, have been treated with the Neuradiab
therapy regimen, and survival benefits have significantly exceeded
historical controls in eac
|SOURCE Bradmer Pharmaceuticals Inc.|
Copyright©2008 PR Newswire.
All rights reserved